Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Battaglia, Giuseppe ^a   Molinaro, Gemma ^a   Riozzi, Barbara ^a   Storto, Marianna ^a   Busceti, Carla L ^a   Spinsanti, Paola ^b   Bucci, Domenico ^a   Di Liberto, Valentina ^c   Mudò, Giuseppina ^c   Corti, Corrado ^d   Corsi, Mauro ^d   Nicoletti, Ferdinando ^a,b   Belluardo, Natale ^c   Bruno, Valeria ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TYROSINE 3 MONOOXYGENASE; AMINO ACID; FUSED HETEROCYCLIC RINGS; METABOTROPIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME ACTIVATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEREOLOGY; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG POTENTIATION; GENETICS; METABOLISM; NERVE CELL; POLYMERASE CHAIN REACTION;

MUS;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CORPUS STRIATUM; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IN SITU HYBRIDIZATION; MICE; NEURONS; POLYMERASE CHAIN REACTION; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER;

EID: 68949151921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006591     Document Type: Article

References (61)

1. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 19: 267-271.
2. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, et al. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033.
3. Lovinger DM (1991) Trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) decreases synaptic excitation in rat striatal slices through a presynaptic action. Neurosci Lett 129: 17-21.
4. Lovinger DM, McCool BA (1995) Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73: 1076-183.
5. Battaglia G, Monn JA, Schoepp DD (1997) In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161-164.
6. Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Luneia R, et al. (1997) Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1'S,2'S,3'R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur J Neurosci 9: 1350-1355.
7. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26.
8. Sharon D, Vorobiov D, Dascal N (1997) Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes. J Gen Physiol 109: 477-490.
9. Bruno V, Sureda FX, Storto M, Casabona G, Caruso A, et al. (1997) The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci 17: 1891-1897.
10. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, et al. (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β. J Neurosci 18: 9594-9600.
11. Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D'Alimonte I, et al. (1999) Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27: 275-281.
12. D'Onofrio M, Cuomo L, Battaglia G, Ngomba TR, Storto M, et al. (2001) Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem 78: 435-445.
13. +-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 76: 351-360.
14. Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, et al. (2007) The use of knockout mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection. J Neurosci 27: 8297-308.
15. Conn JP, Battaglia G, Marino MJ, Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6: 787-798.
16. Venero JL, Santiago M, Tomas-Camardiel M, Matarredona ER, Cano J, et al. (2002) DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neuroscience 113: 857-869.
17. Battaglia G, Fornai F, Busceti LC, Aloisi G, Cerrito F, et al. (2002) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci 22: 2135-2141.
18. Battaglia G, Busceti LC, Pontarelli F, Fornai F, Paparelli A, et al. (2003) Protective role of group-II metabotropic glutamate receptors against nigrostriatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45: 155-166.
19. Battaglia G, Busceti LC, Molinaro G, Biagioni F, Storto M, et al. (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24: 828-835.
20. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Traficante F, et al. (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigro-striatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26: 7222-7229.
21. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, et al. (2005) Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033: 216-220.
22. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
23. Gash DM, Zhang Z, Gerhardt G (1998) Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44: S121-S125.
24. Kordower JH (2003) In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53: S120-S132.
25. Eslamboli A (2005) Assessment in primate models of Parkinson's disease: comparison with human studies. Rev Neurosci 16: 303-310.
26. Bespalov MM, Saarma M (2007) GDNF family complexes are emerging drug targets. Trends Pharmacol Sci 28: 68-74.
27. Schober A, Peterziel H, von Bartheld CS, Simon H, Krieglstein K, et al. (2007) GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action. Neurobiol Dis 25: 378-91.
28. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, et al. (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42: 1027-1040.
29. Schiefer J, Sprünken A, Puls C, Lüesse HG, Milkereit A, et al. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 1019: 246-254.
30. Greco B, Invernizzi RW, Carli M (2005) Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGlu(2/3) receptor agonist LY379268. Psychopharmacology 179: 68-76.
31. Olive MF, Becker HC (2008) Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice. Alcohol 42: 191-197.
32. Osikowicz M, Mika J, Makuch W, Przewlocka B (2008) Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain 139: 117-26.
33. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196: 431-440.
34. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
35. Fell MJ, Svensson KA, Johnson BG, Schoepp DD (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6- dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326: 209-217.
36. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93-97.
37. Schmidt-Kastner R, Tomac A, Hoffer B, Bektesh S, Rosenzweig B, et al. (1994) Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Brain Res Mol Brain Res 26: 325-330.
38. Nosrat CA, Tomac A, Lindqvist E, Lindskog S, Humpel C, et al. (1996) Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res 286: 191-207.
39. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38: 1431-1476.
40. Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
41. Schober A, Hertel R, Arumae U, Farkas L, Jaszai J, et al. (1999) Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-b as cofactor in vivo. J Neurosci 19: 2008-2015.
42. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS, et al. (1994) TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 13: 1245-1252.
43. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, et al. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
44. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
45. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, et al. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222.
46. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived growth factor infusion in Parkinson's disease. Ann Neurol 59: 459-466.
47. Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, et al. (2008) PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 22: 2488-2497.
48. Mandel SA, Sagi Y, Amit T (2007) Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 32: 1694-1699.
49. Weinreb O, Amit T, Bar-Am O, Youdim MB (2007) Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 1122: 155-168.
50. Konieczny J, Ossowska K, Wolfarth S, Pilc A (1998) LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn Schmiedebergs Arch Pharmacol 358: 500-502.
51. Dawson L, Chadha A, Megalou M, Duty S (2000) The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 129: 541-546.
52. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, et al. (1996) Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 273: 645-647.
53. Rose K, Goldberg MP, Choi DW (1992) Cytotoxicity in murine neocortical cell cultures. In: Tyson CA, Frazier JM, eds. Methods in toxicology, Vol. 1, In Vitro Biological System. San Diego: San Diego Academics. pp 46-60.
54. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. London: Academic.
55. Trupp M, Belluardo N, Funakoshi H, Ibanez CF (1997) Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 17: 3554-3567.
56. Lehmann A. Atlas stereotaxique du cerveau de la souris. Ed. Du centre National de la recherche, Paris, 1974.
57. Belluardo N, Olsson PA, Mudo' G, Sommer WH, Amato G, et al. (2005) Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience 133: 787-796.
58. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, et al. (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Acta Pathol Microbiol Immunol Scand 96: 857-881.
59. Gundersen HJG, Jensen EB, Kiâu K, Nielsen J (1999) The efficiency of systematic sampling in stereology: reconsidered. J Microsc 193: 199-211.
60. Pakkenberg B, Gundersen HJG (1988) Total number of neurons and glial cells in human brain nuclei estimated by disector and fractionator. J Microsc 150: 1-20.
61. Mayhew TM, Gundersen HJG (1996) "If you assume, you can make an ass out of u and me": a decade of the dissector for stereological counting of particles in 3D space. J Anat 188: 1-15.